Company Introduction_Weihe Biotechnology INC

Weihe Biotechnology is a pioneer in the transplant diagnosis and transfusion molecular diagnosis industry in China. Its headquarters were established in 2014 in the "China Pharmaceutical City" in Taizhou, Jiangsu Province. Focusing on the dual wheel drive development model of "product+service", it promotes the two strategic development directions of "import substitution" for transplant diagnosis products and "molecular and precision" for transfusion medical diagnosis, and participates in the formulation of multiple national standards and standard products in the industry; It is a national high-tech enterprise, a private science and technology enterprise in Jiangsu Province, and a technology-based small and medium-sized enterprise in Jiangsu Province; Received multiple honors, including the Jiangsu Province Double Innovation Plan Talent, Taizhou 113 Plan Talent, National Science and Technology Innovation Fund for Small and Medium sized Enterprises, and Key Projects of the National Development and Reform Commission's "High end Medical Devices and In Vitro Diagnostic Reagents" Agglomeration Zone Plan.
We have a standard laboratory of approximately 2000 square meters, including multiple standard PCR laboratories. We also have purification plants of approximately 1000 square meters, including one production line for Class III nucleic acid and one production line for Class II protein in vitro diagnostic reagents. We also have production and operation licenses and import and export licenses for Class II and III in vitro diagnostic reagents.
       There is a third-party medical laboratory called Jianxin Medical Examination established in Taizhou, Jiangsu. We have a comprehensive quality management system and experienced R&D, registration, clinical, and production personnel. At the same time, Weihe Southwest Center and Medical Examination Center will be established in Yibin, Sichuan. More than 30 products have completed research and development, and have been used or tested in clinical and research institutions; Multiple products have obtained Class I, II, III and EU CE registration certificates; Completed investment exceeding 100 million yuan.
       We adhere to the company philosophy of "handling things according to heart, being brave, diligent, scientific, and benefiting the world and the people". We are committed to improving the core competitiveness of China's molecular diagnosis field with our advanced technological advantages and scientific and rigorous work attitude, creating a new era of "Made in China" image, and driving the development of the domestic in vitro diagnosis industry.